anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Social anxiety disorder (SAD) is among the most common psychiatric conditions and is associated with significant distress and dysfunction in social situations. Although treatment with cognitive-behavior therapy (CBT) is known to help remedy SAD, many patients do not respond to this treatment and most do not reach full recovery. In CBT, patients undergo repeated and prolonged exposure practices to feared social situations to learn better ways to deal with anxiety in these settings. Exposure therapy is based on animal models of extinction of conditioned fears, and recent animal research has identified some of the core pathways and neurotransmitters involved in fear extinction. D-cycloserine (DCS) is a drug that appears to facilitate learning and the process of extinction of conditioned fear in both animals and humans. This study will assess the effectiveness of DCS combined with CBT in treating people with SAD.

Participants in this double-blind study will be randomly assigned to an active or control group. All participants will attend 18 study visits at the Center for Anxiety and Related Disorders over a 9-month period. There will be 12 CBT sessions of 90 minutes each and 6 assessment visits. The CBT sessions will help participants to become more comfortable with social situations. During 5 of the CBT sessions, participants will receive a pill containing either DCS or sugar (placebo). Assessment visits will include interviews, self-report questionnaires, and laboratory tests. These visits will occur at Weeks 1, 7, and 12 during treatment and at Months 3, 6, and 9 post-treatment.
Glucocorticoids are widely used in the treatment of allergic and inflammatory diseases. Glucocorticoids have a widespread action on gene expression resulting in their pharmacological actions and also an array of adverse effects which limit their clinical use. It remains, however, to be studied which target gene effects are essential for the anti-allergic activity of glucocorticoids. Mitogen-activated protein kinase phosphatase-1 (MKP-1) inhibits proinflammatory signalling by suppressing the activity of mitogen activated protein kinase (MAP kinase) pathways. MKP-1 is one of the anti-inflammatory genes whose expression is enhanced by glucocorticoids. In the present study, we aimed to investigate the role of MKP-1 in the therapeutic effects of the glucocorticoid dexamethasone in acute allergic reaction. The effects of dexamethasone were studied in wild-type and MKP-1 deficient mice. The mice were first sensitized to ovalbumin, and the allergic reaction was then induced by a subcutaneous ovalbumin injection in the hind paw. Inflammatory edema was quantified with plethysmometer and expression of inflammatory factors was measured by quantitative reverse transcription polymerase chain reaction (RT-PCR). Dexamethasone reduced the ovalbumin-induced paw edema at 1.5, 3 and 6 h time points in wild-type mice by 70%, 95% and 89%, respectively. The effect was largely abolished in MKP-1 deficient mice. Furthermore, dexamethasone significantly attenuated the expression of ovalbumin-induced inflammatory factors cyclooxygenase-2 (COX-2); inducible nitric oxide synthase (iNOS); interleukins (IL) 1β, 6 and 13; C-C motif chemokine 11 (CCL-11); tumour necrosis factor (TNF) and thymic stromal lymphopoietin (TSLP) in wild-type mice by more than 40%. In contrast, in MKP-1 deficient mice dexamethasone had no effect or even enhanced the expression of these inflammatory factors. The results suggest that dexamethasone alleviates allergic inflammation through an MKP-1-dependent mechanism. The results also demonstrate MKP-1 as an important conveyor of the favourable glucocorticoid effects in ovalbumin-induced type I allergic reaction. Together with previous findings, the present study supports the concept of MKP-1 enhancing compounds as potential novel anti-inflammatory and anti-allergic drugs.
A counterbalanced design will be used with each male subject receiving placebo and each of the anti-histamine low (12.5 mg) and high (25 mg) doses in a counterbalanced order to keep order of administration from being confounded with dose level. By the time they finish, they will have all received placebo, 12.5mg meclizine and 25mg meclizine. The subject, study coordinator, co-investigator and outcomes assessor will remain blinded to what they received until data analysis is completed.
Obesity, which leads to metabolic dysregulation and body function impairment, emerges as one of the pressing health challenges worldwide. Excessive body fat deposits comprise a dynamic and biologically active organ possessing its own endocrine function. One of the mechanisms underlying the pathophysiology of obesity is low-grade systemic inflammation mediated by pro-inflammatory factors such as free fatty acids, lipopolysaccharides, adipokines (including leptin, resistin and visfatin) and cytokines (TNF-α, IL-1β, Il-6), which are secreted by adipose tissue. Together with obesity-induced insulin resistance and hyperandrogenism, the exacerbated immune response has a negative impact on the hypothalamic-pituitary-gonadal axis at all levels and directly affects reproduction. In women, it results in disrupted ovarian function, irregular menstrual cycles and anovulation, contributing to infertility. This review focuses on the abnormal intracellular communication, altered gene expression and signaling pathways activated in obesity, underscoring its multifactorial character and consequences at a molecular level. Extensive presentation of the complex interplay between adipokines, cytokines, immune cells and neurons may serve as a foundation for future studies in search of potential sites for more targeted treatment of reproductive disorders related to obesity.
Disclosed are an oral tablet manufacturing apparatus and its manufacturing method. The apparatus includes a tablet manufacturing area, a micro control unit, and a material picking area. The tablet manufacturing area includes a tablet spraying device. The tablet spraying device has a roller and a piezoelectric nozzle. A medicine powder filling container is in communication with the piezoelectric nozzle. The medicine powder filling container contains a plurality of medicine powders, and the medicine powders are sprayed and printed through the piezoelectric nozzle. Then, the medicine powders are pressed and flattened by the rollers, so as to form a tablet from the medicine powders. The micro control unit is disposed in the piezoelectric nozzle. The micro control unit has a storage module and an execution control module. The storage module stores tablet spraying information. The execution control module controls the tablet spraying device through the tablet spraying information. The material picking area is used to collect the tablets.
A method of synthesizing hydroxyapatite nanorods, having high purity, high crystallinity and high aspect ratio is disclosed here. In one embodiment, high crystalline hydroxyapatite nanorods with relatively stoichiometric structure are prepared via hydrothermal method at 200° C. and under moderate acidic conditions. The synthesized hydroxyapatite nanorods have a diameter of 30-95 nm, a length of 850-1400 nm with an average aspect ratio of 24, degree of crystallinity of 73% and stoichiometry ratio of 1.69. Further it discloses the use of HAp in dental adhesive. The dental adhesive comprising synthesized HAp shows improved diametral tensile strength and high microshear bond strength. Energy dispersive X-ray mapping confirmed the uniform distribution of nanorods in the adhesive matrix. The synthesized hydroxyapatite nanorods have high colloidal stability in the dental adhesive solution. The nanorods are well dispersed and protected from aggregation by their high surface charges confirmed by zeta potential measurement.
PROBLEM TO BE SOLVED: To obtain the subject emulsion having extremely high stability and capable of holding a large amount of aqueous phase component by applying a specific shearing force to a component containing a hydrophilic surfactant, an oil and water and dispersing the obtained O/W-type microemulsion in an oil phase. SOLUTION: The objective microemulsion is produced by emulsifying a component containing (A) a hydrophilic surfactant (e.g. potassium laurylsulfate or N-lauryl β-alanine), (B) an oil (e.g. liquid paraffin) and (C) water e.g. with a high-pressure homogenizer under a pressure of >=400 atm to obtain an O/W-type emulsion having an average particle diameter of preferably 0.01-0.2 μm and dispersing the emulsion in an oil phase (e.g. by using a disperser). The amount of the component A is preferably 0.01-1 wt.% based on the objective O/W/O-type emulsion.
The invention relates to the field of medicines, in particular to a nano liposome and a preparation method thereof. In particular, the invention relates to butylphthalide nanoliposome powder injection for treating acute ischemic cerebral apoplexy and a preparation method thereof. The nano liposome mainly comprises butylphthalide or levo butylphthalide, phospholipid, cholesterol, long circulation material, negative charge material, protective agent and pH regulator. The invention adopts a film dispersion method and a mixing cavity preparation method to prepare the butylphthalide nanoliposome, and the mixing cavity technology is easier to realize linear amplification and is more suitable for amplifying production scale. The invention adopts liposome inclusion solubilization, completely abandons the use of sulfobutyl-beta-cyclodextrin and other types of cyclodextrin, reduces toxic and side effects, improves therapeutic indexes and improves medication safety. The freeze-dried powder injection has high stability and is convenient to store and transport. The butylphthalide nano-liposome freeze-dried powder injection has simple preparation process and easy amplification, thereby having extremely high industrialized application value.
Patients with an hypertensive crisis during pregnancy will receive 20 mg of Labetalol IV. After 15 minutes if the crisis continue, 40 mg IV. After 15 minutes if the crisis continue, 80 mg IV. Then, if the crisis continue, 80 mg IV every 15 minutes (maximum dose: 300 mg IV in total).
The invention relates to the field of medicines, and provides a Chinese medicinal preparation for treating allergic conjunctivitis. The allergic conjunctivitis is a common ocular surface disorder which has high incidence rate and is difficult to treat, wherein extreme ocular itching is the main symptom of the allergic conjunctivitis clinically, severe visual deterioration can be brought to a severely affected patient, and 3/4 of patients have histories of asthma, allergic rhinitis and other extraocular allergic diseases. Currently, ocular local eye ointment treatment is a main method for treating the allergic conjunctivitis, most treatment only can relieve symptoms and has short time of the curative effect, and the disease easily relapses and is difficult to radically cure clinically. According to holism concept and treatment based on syndrome differentiation, a little pricklyash peel is added based on the traditional effects of 'dispelling wind, clearing heat and relieving itching', and the Chinese medicinal preparation achieves excellent curative effect in clinical treatment. The preparation is prepared from fineleaf schizonepeta herb, divaricate saposhnikovia root, belvedere fruit, fructus cnidii, szechwan lovage rhizome, anemarrhena and pricklyash peel, and has the effects of dispelling wind, clearing heat and relieving itching. The preparation is decocted by a decocting machine, is taken 175ml each time and twice a day, and is constantly taken orally for 1 week as a course of treatment. After the preparation is taken for 3 to 4 courses of treatment, the effective rate is over 96 percent.
The invention discloses an efficient florfenicol powder composition and a preparation method thereof. The powder composition comprises the following components in percentage by weight: 1-50% of florfenicol, 46-98.9% of a florfenicol-absorbed carrier and 0.05-4% of a florfenicol absorption promoter. The method comprises the following steps of: preparing the raw materials according to the above components; preparing a florfenicol organic solvent solution; dissolving the florfenicol absorption promoter and the florfenicol-absorbed carrier into water to obtain a mixed water solution; and adding the florfenicol organic solvent solution into the mixed water solution, and rapidly spray-drying. The preparation method disclosed by the invention is simple and low in cost. The product disclosed by the invention has the advantages of extrinsic quick release, esoteric quick absorption, high plasma peak concentration, thorough drug absorption and less antibiotic residue. The product disclosed by the invention can be applied to the treatment of infection on all parts of domestic animals caused by bacteria.
Patients in the intervention group will receive twice daily supportive text messages to their mobile phone for 6 months following discharge from a 4-week in-patient dual diagnosis treatment programme. The messages will be sent by a computer programme at 10am and 7pm each day and will be set up and monitored by the research worker who will not participate in follow-up assessments. They will receive a fortnightly text message thanking them for participating in the study, and a brief phone call every 2 weeks to ensure that they are still using their phone and that they have received some messages. The intervention group will also receive treatment as usual, i.e. any follow-up after-care that they chose to participate in and regular AA/Lifering meetings.
The invention discloses a medicine for treating male sterility. The medicine consists of the following Chinese herbal medicines by weight/piece: 1 to 3 sheep kidneys, 1 sheep penis, 1 pair of sheep ectonephridiums, 25 to 75 grams of eucommia, 1 to 5 grams of pepper, 7 to 17 grams of ginger, 3 spring onions and 2 grams of salt. A preparation method for the medicine comprises the following steps of: slicing the sheep kidneys of which the panniculus adiposus is removed, the sheep penis and the sheep ectonephridiums; decocting the slices together with the eucommia, the pepper, the ginger and the spring onions to obtain decoction; and adding 2 grams of salt for seasoning. The medicine for treating the male sterility has the advantages that: all Chinese medicinal compositions, namely the sheep kidneys, the sheep penis, the sheep ectonephridiums and the eucommia are combined together to achieve the effects of tonifying kidney and strengthening yang, and tonifying qi and generating sperms; the pepper and the ginger have the effects of regulating five internal organs and dispelling cold; the spring onions have the effects of sweating, deflocculating, activating yang and dispelling cold; and the salt has the effect of dispelling fishy smell and mutton taste. Therefore, the medicine has the effects of tonifying the kidney and strengthening yang, tonifying qi and generating the sperms, dispelling the cold, deflocculating, promoting the generation of the sperms and enhancing the activity of the sperms. The invention has the characteristics that: the medicine is a Chinese medicinal preparation and does not have toxic and side effects.
Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including clindamycin and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C.difficile.

Because clindamycin therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate, as described in the INDICATIONS AND USAGE section. It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections. C.difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C.difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C.difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.difficile, and surgical evaluation should be instituted as clinically indicated.

DESCRIPTION

Clindamycin palmitate hydrochloride is a water soluble hydrochloride salt of the ester of clindamycin and palmitic acid. Clindamycin is a semisynthetic antibiotic produced by a 7(S)-chlorosubstitution of the 7(R)-hydroxyl group of the parent compound lincomycin.

The structural formula is represented below:

The chemical name for clindamycin palmitate hydrochloride is Methyl 7-chloro-6, 7, 8-trideoxy- 6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-α-D-galacto octopyranoside 2- palmitate monohydrochloride.

Clindamycin palmitate hydrochloride for oral solution Flavored Granules contain clindamycin palmitate hydrochloride for reconstitution. Each 5 mL contains the equivalent of 75 mg clindamycin. Inactive ingredients: cherry powder, dextrin, ethylparaben, poloxamer P188, simethicone and sugar.
Data from the scientific literature support the hypothesis that bioactive lipids play an important role in inflammatory disorders. The levels of these bioactive lipids are altered in several pathophysiological conditions with an inflammatory component. The investigators and others have demonstrated that bioactive lipids affect the inflammatory tone in vivo in murine models as well as in in vitro models. However, confirming the translational value of these data is not easy in clinical studies. PBMC-based experiments are a powerful tool for us to validate our previous observations and will offer translational added value supporting further clinical investigations.

Thus, here the investigators aim at harvesting PBMC from healthy donors and use them to study the effect of the lipid mediators of interest (i.e. those showing interesting properties in our preclinical models). Blood will be collected from healthy volunteers, and PMBC isolated based on their density. After isolation from the blood, PBMC will be activated as largely reported in the literature (e.g. using phytohemagglutinin or lipopolysaccharides) in the presence or absence of the tested lipids. The effect will be assessed by quantifying the expression of inflammatory markers (by RT-qPCR and/or ELISA). The expression of the receptors and enzymes potentially regulating the effects of the studied lipids will be also assessed (by RT-qPCR).
The invention belongs to the field of chemical medicines, and particularly relates to a pyridone derivative, a preparation method and an application thereof. The pyridone derivative is represented as the formula (I). The invention also provides the preparation method of the pyridone derivative and the application thereof in preparation of a drug for treating tumor. The preparation method is short in synthetic route, is simple in reaction conditions, is high in yield and is easy for derivatization. The compounds in the invention have high anti-tumor activity and low toxicity. The invention provides a new selection for preparing an anti-tumor drug.
The present invention relates to a compound solid preparation and the preparation method therefor, and specifically relates to a valsartan-amlodipine compound solid preparation and the preparation method therefor. The valsartan-amlodipine compound solid preparation comprises valsartan particles and an amlodipine premix. The valsartan particles are prepared as follows: using an aqueous solution of ethanol as a wetting agent, and mixing valsartan and medicinal supplements; producing wet particles from the mixture; drying to produce valsartan particles. The amlodipine premix is prepared as follows: mixing amlodipine and medicinal supplements to produce the amlodipine premix. The valsartan-amlodipine compound solid preparation and the preparation method therefor of the present invention can prevent the mutual effect between the two main ingredients, amlodipine and valsartan. The preparation method is relatively simple and is suitable for large-scale industrial production.
Within intensive care units (ICU), the administration of peptide-based formulas (PBF) may confer nutritional advantages for critically ill patients identified with heightened nutritional risk. This investigation aimed to ascertain the efficacy of PBF in comparison to standard polymeric formulas (SPF) among this patient cohort. A double-blind, randomized controlled trial was conducted across three ICUs, encompassing 63 adult patients characterized by elevated modified Nutrition Risk in Critically Ill (mNUTRIC) scores. Enrollment occurred promptly subsequent to ICU admission, with participants allocated to receive either PBF or SPF. Primary outcome was the duration to achieve caloric targets. Secondary outcomes involved the evaluation of mean daily gastric residual volume, mechanical ventilation period, infection rates within the ICU, length of hospitalization, mortality rates, nutritional status and inflammatory markers, specifically serum albumin and interleukin-6 levels. Patients in the PBF group reached their caloric targets more expeditiously compared to the SPF group (2.06 ± 0.43 days versus 2.39 ± 0.79 days; p = 0.03). No significant differences were discernible between the groups regarding gastric residual volume, duration of mechanical ventilation, ICU length of stay, mortality, or infection rates. Both cohorts exhibited minimal adverse effects and were devoid of any instances of abdominal distension. While not reaching statistical significance, the observed trends in albumin and interleukin-6 levels suggest a potential advantage of PBF utilization. The implementation of PBF enabled swifter attainment of caloric goals in ICU patients at high nutritional risk without adversely impacting other clinical parameters. Given its favorable tolerance profile and potential immunomodulatory properties, PBF may be considered a valuable nutritional intervention in this setting.Thai Clinical Trials Registry TCTR20220221006. Registered 21 February 2022, https://www.thaiclinicaltrials.org/show/TCTR20220221006 .
OBJECTIVE: To examine association of costs with quality of care and patient outcome across hospitals in California.
METHODS: Retrospective study of very low birth weight (VLBW) births from 2014-2018 linking birth certificate, hospital discharge records and clinical data. Quality was measured using the Baby-MONITOR score. Clinical outcome was measured using survival without major morbidity (SWMM). Hierarchical generalized linear models, adjusting for clinical factors, were used to estimate risk-adjusted measures of costs, quality, and outcome for each hospital. Association between these measures was evaluated using Pearson correlation coefficient.
RESULTS: In total, 15,415 infants from 104 NICUs were included. Risk-adjusted Baby-MONITOR score, SWMM rate, and costs varied substantially. There was no correlation between risk-adjusted cost and Baby-MONITOR score (r = 0, p = 0.998). Correlation between risk-adjusted cost and SWMM rate was inverse and not significant (r = -0.07, p = 0.48).
CONCLUSIONS: With the metrics used, we found no correlation between cost, quality, and outcomes in the care of VLBW infants.